Cargando…
Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine
Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) is a highly pathogenic and transmissible virus. Infection caused by SARS-CoV-2 known as Coronavirus disease 2019 (COVID-19) can be severe, especially among high risk populations affected of underlying medical conditions. COVID-19 is charac...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385778/ https://www.ncbi.nlm.nih.gov/pubmed/35998506 http://dx.doi.org/10.1016/j.intimp.2022.109161 |
_version_ | 1784769663148752896 |
---|---|
author | Shirzad, Moein Nourigorji, Marjan Sajedi, Atefe Ranjbar, Maryam Rasti, Faeze Sourani, Zahra Moradi, Mona Mostafa Mir, Seyed Memar, Mohammad Yousef |
author_facet | Shirzad, Moein Nourigorji, Marjan Sajedi, Atefe Ranjbar, Maryam Rasti, Faeze Sourani, Zahra Moradi, Mona Mostafa Mir, Seyed Memar, Mohammad Yousef |
author_sort | Shirzad, Moein |
collection | PubMed |
description | Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) is a highly pathogenic and transmissible virus. Infection caused by SARS-CoV-2 known as Coronavirus disease 2019 (COVID-19) can be severe, especially among high risk populations affected of underlying medical conditions. COVID-19 is characterized by the severe acute respiratory syndrome, a hyper inflammatory syndrome, vascular injury, microangiopathy and thrombosis. Antiviral drugs and immune modulating methods has been evaluated. So far, a particular therapeutic option has not been approved for COVID-19 and a variety of treatments have been studied for COVID-19 including, current treatment such as oxygen therapy, corticosteroids, antiviral agents until targeted therapy and vaccines which are diverse in each patient and have various outcomes. According to the findings of different in vitro and in vivo studies, some novel approach such as gene editing, cell based therapy, and immunotherapy may have significant potential in the treatment of COVID-19. Based on these findings, this paper aims to review the different strategies of treatment against COVID-19 and provide a summary from traditional and newer methods in curing COVID-19. |
format | Online Article Text |
id | pubmed-9385778 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93857782022-08-18 Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine Shirzad, Moein Nourigorji, Marjan Sajedi, Atefe Ranjbar, Maryam Rasti, Faeze Sourani, Zahra Moradi, Mona Mostafa Mir, Seyed Memar, Mohammad Yousef Int Immunopharmacol Article Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) is a highly pathogenic and transmissible virus. Infection caused by SARS-CoV-2 known as Coronavirus disease 2019 (COVID-19) can be severe, especially among high risk populations affected of underlying medical conditions. COVID-19 is characterized by the severe acute respiratory syndrome, a hyper inflammatory syndrome, vascular injury, microangiopathy and thrombosis. Antiviral drugs and immune modulating methods has been evaluated. So far, a particular therapeutic option has not been approved for COVID-19 and a variety of treatments have been studied for COVID-19 including, current treatment such as oxygen therapy, corticosteroids, antiviral agents until targeted therapy and vaccines which are diverse in each patient and have various outcomes. According to the findings of different in vitro and in vivo studies, some novel approach such as gene editing, cell based therapy, and immunotherapy may have significant potential in the treatment of COVID-19. Based on these findings, this paper aims to review the different strategies of treatment against COVID-19 and provide a summary from traditional and newer methods in curing COVID-19. Elsevier B.V. 2022-10 2022-08-18 /pmc/articles/PMC9385778/ /pubmed/35998506 http://dx.doi.org/10.1016/j.intimp.2022.109161 Text en © 2022 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Shirzad, Moein Nourigorji, Marjan Sajedi, Atefe Ranjbar, Maryam Rasti, Faeze Sourani, Zahra Moradi, Mona Mostafa Mir, Seyed Memar, Mohammad Yousef Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine |
title | Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine |
title_full | Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine |
title_fullStr | Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine |
title_full_unstemmed | Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine |
title_short | Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine |
title_sort | targeted therapy in coronavirus disease 2019 (covid-19): implication from cell and gene therapy to immunotherapy and vaccine |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385778/ https://www.ncbi.nlm.nih.gov/pubmed/35998506 http://dx.doi.org/10.1016/j.intimp.2022.109161 |
work_keys_str_mv | AT shirzadmoein targetedtherapyincoronavirusdisease2019covid19implicationfromcellandgenetherapytoimmunotherapyandvaccine AT nourigorjimarjan targetedtherapyincoronavirusdisease2019covid19implicationfromcellandgenetherapytoimmunotherapyandvaccine AT sajediatefe targetedtherapyincoronavirusdisease2019covid19implicationfromcellandgenetherapytoimmunotherapyandvaccine AT ranjbarmaryam targetedtherapyincoronavirusdisease2019covid19implicationfromcellandgenetherapytoimmunotherapyandvaccine AT rastifaeze targetedtherapyincoronavirusdisease2019covid19implicationfromcellandgenetherapytoimmunotherapyandvaccine AT souranizahra targetedtherapyincoronavirusdisease2019covid19implicationfromcellandgenetherapytoimmunotherapyandvaccine AT moradimona targetedtherapyincoronavirusdisease2019covid19implicationfromcellandgenetherapytoimmunotherapyandvaccine AT mostafamirseyed targetedtherapyincoronavirusdisease2019covid19implicationfromcellandgenetherapytoimmunotherapyandvaccine AT memarmohammadyousef targetedtherapyincoronavirusdisease2019covid19implicationfromcellandgenetherapytoimmunotherapyandvaccine |